Evidence map›Paper›PMID 41090323›Full record

ArticleCell biology international2025

Synergistic Reduction of Breast Cancer Cell Viability and Aggressiveness Through Dual Inhibition of APE1 Redox Function and STAT3 Signaling.

Mariana Moreno de Sousa Rodrigues, Priscyanne Barreto Siqueira, Ana Clara Cavallo Dobao, Maria Eduarda Barbosa Mourão, Bruno Ricardo Barreto Pires, Adenilson de Souza da Fonseca, Ísis Salviano Soares de Amorim, Andre Luiz Mencalha

Abstract read
In one paragraph

Article in Cell biology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mariana Moreno de Sousa RodriguesDepartamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Laboratório de Biologia do Câncer, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0003-0224-7288
Priscyanne Barreto SiqueiraDepartamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Laboratório de Biologia do Câncer, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Ana Clara Cavallo DobaoDepartamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Laboratório de Biologia do Câncer, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Maria Eduarda Barbosa MourãoDepartamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Laboratório de Biologia do Câncer, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Bruno Ricardo Barreto PiresDepartamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Laboratório de Biologia do Câncer, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Adenilson de Souza da FonsecaDepartamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Laboratório de Biofotônica, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Ísis Salviano Soares de AmorimDepartamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Laboratório de Biologia do Câncer, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Andre Luiz MencalhaDepartamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Laboratório de Biologia do Câncer, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.

Funding

This study was supported by FAPERJ, CNPq and CAPES.
6 · The paper itself

Abstract

Aggressiveness and resistance to treatments are significant problems in cancer management. In this scenario, searching for new pharmacological targets for therapies is essential. The APE1 redox domain coactivates transcription factors that favor cancer malignancy. One of APE1's targets, STAT3, coordinates the transcription of genes involved in cancer hallmarks. However, the association between APE1 and STAT3 in the context of breast cancer cell survival and aggressiveness has not been previously characterized. Therefore, we investigated the role of the redox function of APE1 and STAT3 inhibitors in cell viability, proliferation, migration, invasion, and cell death. In addition, we verified the association between APE1 and STAT3 in breast cancer patient samples from TCGA and their relationship with proliferation and metastasis. Our results suggest that combined treatment with APE1 and STAT3 inhibitors can further synergistically reduce cell viability, proliferation, migration, and invasion, compared to treatment with inhibitors alone. Moreover, the APE1 and STAT3 activity levels positively correlated with proliferation and metastasis gene signatures. Thus, we suggest the APE1 redox domain and STAT3 as promising targets for new therapy strategies against breast cancer.

Indexed as

Breast NeoplasmsDNA-(Apurinic or Apyrimidinic Site) LyaseSTAT3 Transcription FactorCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleHumansNeoplasm InvasivenessOxidation-ReductionSignal TransductionAPEX1 protein, humanDNA-(Apurinic or Apyrimidinic Site) LyaseSTAT3 protein, humanSTAT3 Transcription FactoraggressivenessAPE1breast cancerSTAT3

Identifiers

PMID41090323
PMCPMC12605823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.